相关实验视频

Updated: Jul 12, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

改善患者在免疫媒介炎症疾病中获得生物类似瘤缩因子抑制剂的机会:从挪威学到的教训

Guro L Goll¹, Tore K Kvien^1,2

¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.

Expert opinion on biological therapy

|October 24, 2023

概括

挪威通过利用招标系统和吸引临床医生,成功实施了生物类似TNF抑制剂 (TNFi). 这种方法降低了生物类似药和原始TNFi的成本,为其他国家提供了潜在的模型.

科学领域:

免疫学免疫学免疫学
药物经济学药物经济学
卫生政策卫生政策

背景情况:

瘤坏死因子抑制剂 (TNFi) 对于治疗炎症性疾病至关重要.
在全球范围内,采用具有成本效益的生物类似TNFi的情况各不相同.
挪威已经实现了生物类似TNFi比原始产品的高利用率.

研究的目的:

详细介绍过去十年在挪威实施生物类似TNFi的情况.
确定有助于成功采用和使用生物类似TNFi的关键因素.
将挪威的方法与国际背景进行比较.

主要方法:

对挪威生物药品国家招标和采购系统的分析.
审查临床社区参与,包括专家咨询委员会.
对生物类似药物实施策略的比较评估.

主要成果:

挪威的招标系统显著降低了TNFi成本.
生物类似药的竞争也降低了原始TNFi价格.
与临床专家的早期接触促进了生物类似药的接受.

结论:

挪威的生物制品采购模式可以为其他国家提供信息.
适应国家医疗保健系统和背景对于复制至关重要.
成功实施生物类似TNFi需要战略采购和利益相关者的参与.

关键词:

TNF 抑制剂可以抑制TNF.这就是Adalimumab.生物类似药的生物类似药.乙醇接收剂乙醇接收剂这就是Infliximab.牛皮关节炎牛皮关节炎类风湿性关节炎类风湿性关节炎脊柱性关节炎 (spondyloarthritis) 是一个疾病.

更多相关视频

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...